Full history for every metric is available with a Kvantra account
Hisamitsu Pharmaceutical Co., Inc. (4530.T)
Key financial summary
Financials in JPY| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | ¥bn | 115 | 120 | 128 | 142 | 156 | 163 | 163 |
| Operating profit | ¥bn | 18 | 18 | |||||
| Net profit | ¥bn | 9 | 10 | 12 | 14 | 22 | 19 | 19 |
| EPS reported | ¥ | 268.2 | 268.8 | |||||
| Operating cashflow per share | ¥ | 245.0 | 0.00 | |||||
| Capex per share | ¥ | 112.1 | 0.00 | |||||
| FCF per share | ¥ | 132.9 | 0.00 | |||||
| Free cash flow | ¥bn | 9 | 0 | |||||
| Net debt | ¥bn | -117 | -116 | |||||
| Book value equity | ¥bn | 292 | 292 | |||||
| Book value per share | ¥ | 4,085 | 4,120 | |||||
| Number of shares | m | 71.44 | 70.82 | |||||
| DPS (TTM paid) | ¥ | 106.4 | 60.00 |
Financial summary
Financials in JPY| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | 22.48 | 22.47 | |||||
| P/B LTM | x | 1.47 | 1.46 | |||||
| P/S LTM | x | 2.64 | 2.61 | |||||
| P/FCF LTM | x | 45.37 | 0.00 | |||||
| EV/EBITDA LTM | x | 10.54 | 10.72 | |||||
| EV/Sales LTM | x | 1.99 | 1.90 | |||||
| Earnings Yield LTM | % | 4.45% | 4.45% | |||||
| FCF Yield | % | 2.20% | 0.00% | |||||
| Quality | ||||||||
| ROE | % | 6.57% | 6.99% | |||||
| ROIC | % | 4.66% | 4.66% | |||||
| Operating margin | % | 10.99% | 10.99% | |||||
| Gross margin | % | 58.96% | 58.96% | |||||
| FCF/Sales | % | 5.82% | 0.00% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | -9.12% | -9.12% | |||||
| Sales Growth YoY | % | +4.50% | +4.50% | |||||
| Net Income Growth YoY | % | -11.94% | -11.94% | |||||
| FCF Growth | % | +84.57% | - | |||||
| Operating Profit Growth | % | -5.17% | -5.17% | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 1.76% | 0.99% | |||||
| Dividend Growth | % | - | +36.36% | |||||
| Payout Ratio | % | 39.63% | 39.63% | |||||
| FCF/Debt | x | 3.99 | 0.00 | |||||
| Net Debt/EBITDA | x | -3.47 | -3.69 | |||||
| EBIT/Net interest | x | 853.24 | 853.14 | |||||
| Net debt/market cap | % | -27.29% | -27.34% | |||||
| Net debt/Equity | x | -0.40 | -0.40 | |||||
| Gross debt/equity | x | 0.01 | 0.01 | |||||
Company overview
Hisamitsu Pharmaceutical Co., Inc. is a Japanese enterprise specializing in the development, manufacturing, and distribution of a wide array of healthcare solutions. Its extensive product catalog includes pharmaceuticals, medical devices, quasi-drugs, and cosmetics, catering to markets in Japan, the United States, and Asia. The company is particularly recognized for its comprehensive range of external pain relief medications, featuring popular brands such as SALONPAS, NOBINOBI, SALONSIP, AIR, and FEITAS. Additionally, Hisamitsu offers various transdermal patches for pain and inflammation, including MOHRUS TAPE, MOHRUS PAP XR, FENTOS Tapes, NEOXY Tapes, Abstral, ALLESAGA Tapes, HARUROPI Tapes, and MENOAID Combipatch. Beyond pain management, its portfolio addresses other conditions with products like BUTENALOCK for athlete's foot and ALLEGRA FX for allergy and sinus symptoms. Specialized therapeutic patches for female hormone regulation, asthma, overactive bladders, and the HFT-290 patch for cancer pain further highlight its diverse pharmaceutical offerings. Founded in Tosu, Japan, in 1847, Hisamitsu Pharmaceutical boasts a rich history in the industry.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Hisamitsu Pharmaceutical Co., Inc. (4530.T)
Hisamitsu Pharmaceutical Co., Inc. is a Japanese enterprise specializing in the development, manufacturing, and distribution of a wide array of healthcare solutions. Its extensive product catalog includes pharmaceuticals, medical devices, quasi-drugs, and cosmetics, catering to markets in Japan, the United States, and Asia. The company is particularly recognized for its comprehensive range of external pain relief medications, featuring popular brands such as SALONPAS, NOBINOBI, SALONSIP, AIR, and FEITAS. Additionally, Hisamitsu offers various transdermal patches for pain and inflammation, including MOHRUS TAPE, MOHRUS PAP XR, FENTOS Tapes, NEOXY Tapes, Abstral, ALLESAGA Tapes, HARUROPI Tapes, and MENOAID Combipatch. Beyond pain management, its portfolio addresses other conditions with products like BUTENALOCK for athlete's foot and ALLEGRA FX for allergy and sinus symptoms. Specialized therapeutic patches for female hormone regulation, asthma, overactive bladders, and the HFT-290 patch for cancer pain further highlight its diverse pharmaceutical offerings. Founded in Tosu, Japan, in 1847, Hisamitsu Pharmaceutical boasts a rich history in the industry.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free